Dashboard
Manage Tickers

CELC Celcuity Inc.

Nasdaq celcuity.com


$ 87.00 $ 0.85 (1 %)    

Thursday, 13-Nov-2025 17:37:37 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 608.59 $ -9.26 (-1.5 %)
DIA $ 475.50 $ -6.59 (-1.37 %)
SPY $ 672.57 $ -8.41 (-1.24 %)
TLT $ 89.38 $ -0.42 (-0.46 %)
GLD $ 384.40 $ -4.31 (-1.11 %)
$ 86
$ 85.15
$ 85.00 x 415
$ 93.00 x 200
-- - --
$ 7.58 - $ 87.74
1,200,839
na
3.98B
$ 0.61
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-13-2025 09-30-2025 10-Q
2 08-14-2025 06-30-2025 10-Q
3 05-15-2025 03-31-2025 10-Q
4 03-31-2025 12-31-2024 10-K
5 11-14-2024 09-30-2024 10-Q
6 08-14-2024 06-30-2024 10-Q
7 05-15-2024 03-31-2024 10-Q
8 03-27-2024 12-31-2023 10-K
9 11-13-2023 09-30-2023 10-Q
10 08-11-2023 06-30-2023 10-Q
11 05-15-2023 03-31-2023 10-Q
12 03-23-2023 12-31-2022 10-K
13 11-10-2022 09-30-2022 10-Q
14 08-12-2022 06-30-2022 10-Q
15 05-16-2022 03-31-2022 10-Q
16 03-23-2022 12-31-2021 10-K
17 11-09-2021 09-30-2021 10-Q
18 08-11-2021 06-30-2021 10-Q
19 05-10-2021 03-31-2021 10-Q
20 02-16-2021 12-31-2020 10-K
21 11-09-2020 09-30-2020 10-Q
22 08-10-2020 06-30-2020 10-Q
23 05-07-2020 03-31-2020 10-Q
24 03-13-2020 12-31-2019 10-K
25 11-07-2019 09-30-2019 10-Q
26 08-08-2019 06-30-2019 10-Q
27 05-07-2019 03-31-2019 10-Q
28 03-01-2019 12-31-2018 10-K
29 11-13-2018 09-30-2018 10-Q
30 08-09-2018 06-30-2018 10-Q
31 05-14-2018 03-31-2018 10-Q
32 03-15-2018 12-31-2017 10-K
33 11-13-2017 09-30-2017 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

craig-hallum-maintains-buy-on-celcuity-raises-price-target-to-108
Craig-Hallum Maintains Buy on Celcuity, Ra...
11/13/2025 17:48:50

Craig-Hallum analyst Alexander Nowak maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $96 to $108.

stifel-maintains-buy-on-celcuity-raises-price-target-to-115
Stifel Maintains Buy on Celcuity, Raises P...
11/13/2025 16:00:31

Stifel analyst Stephen Willey maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price target from $68 to $115.

celcuity-q3-adj-eps-078-beats-101-estimate
Celcuity Q3 Adj. EPS $(0.78) Beats $(1.01)...
11/12/2025 21:02:26

Celcuity (NASDAQ:CELC) reported quarterly losses of $(0.78) per share which beat the analyst consensus estimate of $(1.01) by 2...

earnings-scheduled-for-november-12-2025
Earnings Scheduled For November 12, 2025
11/12/2025 11:11:28

exploring-celcuitys-earnings-expectations
Exploring Celcuity's Earnings Expectations
11/11/2025 14:03:35

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-77
HC Wainwright & Co. Maintains Buy on Celcu...
10/22/2025 11:49:48

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

Core News & Articles
12 Health Care Stocks Moving In Monday's I...
10/20/2025 18:39:30

ww-international-replimune-group-datavault-ai-grail-and-other-big-stocks-moving-higher-on-monday
WW International, Replimune Group, Datavau...
10/20/2025 14:13:22

dow-jumps-over-200-points-cleveland-cliffs-shares-jump-after-q3-results
Dow Jumps Over 200 Points; Cleveland-Cliff...
10/20/2025 13:49:54

Core News & Articles
12 Health Care Stocks Moving In Monday's P...
10/20/2025 12:08:17

needham-reiterates-buy-on-celcuity-maintains-70-price-target
Needham Reiterates Buy on Celcuity, Mainta...
10/20/2025 10:10:53

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

why-delcath-systems-shares-are-trading-higher-by-over-14-here-are-20-stocks-moving-premarket
Why Delcath Systems Shares Are Trading Hig...
10/20/2025 09:10:06

reported-saturday-celcuity-presented-phase-1-data-at-esmo-2025-showing-gedatolisib-plus-darolutamide-delivers-91-month-median-rpfs-in-mcrpc-with-favorable-safety-profile-and-no-trae-related-discontinuations
Reported Saturday, Celcuity Presented Phas...
10/20/2025 08:18:12

Median radiographic progression free survival ("rPFS") was 9.1 months and the six-month rPFS rate was 67%No patients di...

reported-saturday-celcuity-announces-phase-3-viktoria-1-data-gedatolisib-triplet-reduces-risk-of-progression-or-death-by-76-in-hrher2--pik3ca-wild-type-advanced-breast-cancer
Reported Saturday, Celcuity Announces Phas...
10/20/2025 08:16:32

Clinical benefit of the gedatolisib regimens was consistent across patient subgroups Hyperglycemia was reported in only 9.2% of...

needham-reiterates-buy-on-celcuity-maintains-70-price-target
Needham Reiterates Buy on Celcuity, Mainta...
10/03/2025 10:38:42

Needham analyst Gil Blum reiterates Celcuity (NASDAQ:CELC) with a Buy and maintains $70 price target.

celcuity-to-present-phase-3-viktoria-1-breast-cancer-data-in-late-breaking-oral-session-at-esmo-2025
Celcuity To Present Phase 3 VIKTORIA-1 Bre...
09/22/2025 13:17:34

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

guggenheim-initiates-coverage-on-celcuity-with-buy-rating-announces-price-target-of-110
Guggenheim Initiates Coverage On Celcuity ...
09/22/2025 10:57:45

Guggenheim analyst Brad Canino initiates coverage on Celcuity (NASDAQ:CELC) with a Buy rating and announces Price Target of ...

celcuitys-nda-for-gedatolisib-in-hrher2--breast-cancer-accepted-into-fdas-real-time-oncology-review-program
Celcuity's NDA For Gedatolisib In HR+/HER2...
08/27/2025 20:14:22

Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, to...

hc-wainwright--co-maintains-buy-on-celcuity-raises-price-target-to-66
HC Wainwright & Co. Maintains Buy on Celcu...
08/18/2025 10:34:59

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Celcuity (NASDAQ:CELC) with a Buy and raises the price targ...

needham-maintains-buy-on-celcuity-lowers-price-target-to-70
Needham Maintains Buy on Celcuity, Lowers ...
08/15/2025 10:05:13

Needham analyst Gil Blum maintains Celcuity (NASDAQ:CELC) with a Buy and lowers the price target from $74 to $70.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION